- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:03 | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | 235 | EQS Group (DE) | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
| 05:52 | OPTHEA LIMITED: Long Term Suspended Entities | - | ASX | ||
| 05:52 | GENETIC TECHNOLOGIES LIMITED: Long Term Suspended Entities | - | ASX | ||
| 05:52 | HEXIMA LIMITED: Long Term Suspended Entities | - | ASX | ||
| 05:34 | Bayer, MustGrow Biologics und Yara International: So holen Sie sich den 40 % Dünger-Preissprung in Ihr Portfolio | 404 | Kapitalerhöhungen.de | Seit Ende Februar 2026 blockiert der Iran-Krieg die Straße von Hormuz und katapultiert Stickstoffdüngerpreise um 40 % nach oben. Während geopolitische Schocks die Lieferketten zerreißen, entstehen für... ► Artikel lesen | |
| 05:18 | Trevi Therapeutics prices $150M stock offering at $13 per share | 4 | Investing.com | ||
| 04:50 | Global Momentum Continues as Immuron Delivers Double-Digit Q3 Sales Growth in Australia | 1 | smallcaps.com.au | ||
| 04:49 | NANOLLOSE LIMITED: Application for quotation of securities - NC6 | - | ASX | ||
| 04:48 | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 03:42 | Telo Genomics Corp (2): Telo Genomics debenture private placement | 3 | Stockwatch | ||
| 03:34 | CHIMERIC THERAPEUTICS LIMITED: Update - Consolidation/Split - CHM | - | ASX | ||
| 03:22 | CHIMERIC THERAPEUTICS LIMITED: Results of Meeting | - | ASX | ||
| 02:35 | Is the Telix share price heading to $19? This broker thinks it is | 3 | The Motley Fool Australia | ||
| 02:06 | Enveric Biosciences raises $5M in private placement | 2 | Investing.com | ||
| 01:30 | BEONE MEDICINES (06160): DIRECTOR NOMINEES AND PROPOSED CHANGES IN BOARD COMMITTEE COMPOSITION | 1 | HKEx | ||
| 00:54 | ALTERITY THERAPEUTICS LIMITED: Alterity Appoints Biotech Executive Ann Cunningham to Board | - | ASX | ||
| 00:40 | ADALTA LIMITED: Board Change and Appendix 3Z | - | ASX | ||
| 00:30 | IMMURON LIMITED: Immuron Double Digit 3Q Sales Growth | - | ASX | ||
| 00:04 | CLINUVEL PHARMACEUTICALS LIMITED: Notification of cessation of securities - CUV | 1 | ASX | ||
| Do | Lytix Biopharma ASA - Conversion to public limited liability company and name change registered | 1 | Cision News |
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| MEIRAGTX | 12 | - | -1,86 % | MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) | Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx... ► Artikel lesen | ||
| CYBIN | 6 | - | +1,71 % | Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs | Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO... ► Artikel lesen | ||
| EVOTEC | 5 | 44 | +0,45 % | Aufgepasst! Riesiges Marktpotenzial im größten Teilbereich der Pharmabranche nutzen: mit Innovator Vidac Pharma, Platzhirsch Bayer oder Turnaround-Kandidat Evotec? | Die Onkologie ist der strategisch wichtigste Wachstumsmarkt der Pharmaindustrie und gleichzeitig einer der entscheidenden Hebel zur Verbesserung der globalen Gesundheit. Aktuell erkranken weltweit rund... ► Artikel lesen | ||
| MESOBLAST | 5 | 3 | +0,95 % | Biotech vor dem Comeback? Warum 2026 einen Führungswechsel bringen könnte - und weshalb Mesoblast in den Fokus rückt | |||
| ACURX PHARMACEUTICALS | 5 | 2 | 0,00 % | New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma, Vivos Therapeutics, Acurx Pharmaceuticals, and Equinox Gold | Special continuing M&A Segment with Senior M&A Partner at Sullivan & Cromwell LLP, Frank Aquila NEW YORK CITY, NY / ACCESS Newswire / April 11, 2026 / New to The Street announces its latest nationally... ► Artikel lesen | ||
| ADLAI NORTYE | 5 | 1 | +10,20 % | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | |||
| ALIGOS THERAPEUTICS | 5 | - | +4,31 % | Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection | Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program... ► Artikel lesen | ||
| TELIX PHARMACEUTICALS | 4 | 1 | +0,31 % | Telix Pharmaceuticals Limited: Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma | MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with... ► Artikel lesen | ||
| TREVI THERAPEUTICS | 4 | - | 0,00 % | Trevi Therapeutics prices $150M stock offering at $13 per share | |||
| AKTIS ONCOLOGY | 4 | - | +2,99 % | Aktis Oncology, Inc. - 8-K, Current Report |
- Alle
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| BIO-GATE AG | 0,540 | 3,40 | +530 % | 1 | - | - | |||
| DARWIN AG | 8,400 | 30 | +257 % | 2 | - | - | |||
| NANOREPRO AG | 1,470 | 4,50 | +206 % | 2 | - | - | |||
| EVOTEC SE | 5,570 | 8,07 | +45 % | 5 | 2 | - | |||
| QIAGEN NV | 35,000 | 50 | +43 % | 8 | 4 | - | |||
| BIONTECH SE ADR | 86,75 | 121,75 | +40 % | 7 | - | - | |||
| SARTORIUS STEDIM BIOTECH SA | 181,40 | 234,17 | +29 % | 8 | 1 | - | |||
| ARGENX SE | 703,00 | 819,25 | +17 % | 6 | 2 | - |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.